JUL 13, 2021 7:00 AM PDT

A Moment of COVID, A Lifetime of Immune Protection?

WRITTEN BY: Tara Fernandez

Does getting vaccinated, or having recovered from COVID, provide life-long protection against the coronavirus? Most likely, says research by immunologists at Washington University in St. Louis, who found antibody-producing cells against the virus residing in the bone marrow of individuals who had previously tested COVID-positive.

This discovery supports the theory that immune responses after exposure to SARS-CoV-2 are robust enough to confer sustained, potentially decades-long protection against the pathogen. In addition, this finding also indicates that vaccines may create a similarly durable shield against COVID in the long run.

Antibody-producing bone marrow plasma cells, or BMPCs, are among the body’s arsenal of immune weapons against invading pathogens, forming a part of what’s known as immunological memory. When the immune system comes across a microbiological threat that it has encountered previously, it launches a more rapid, aggressive, and targeted attack against the offending microbe the second time around.

Earlier studies had suggested that BMPC formation might not occur as effectively in COVID patients as it does in the case of other viral infections, meaning that those who have recovered from COVID may be at risk of reinfection.

However, a study led by BMPC expert Ali Ellebedy found the opposite to be true. The researchers’ analysis of samples obtained from 77 COVID-19 patients revealed that these individuals continued to produce antibodies specific to SARS-CoV-2 up to 11 months after infection. Additionally, 15 of the 18 bone marrow samples collected from these participants showed the presence of coronavirus-specific BMPCs at around a year after infection.

The scientists speculate that vaccines may elicit similar immunological responses, although the emergence of novel variants of SARS-CoV-2 may leave vaccinated individuals vulnerable and in need of “booster” shots for complete protection.

 

Source: NatureNature News.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 06, 2021
Immunology
New Nanotechnology Delivers RNA Drugs Only to "Bad" Immune Cells
JUL 06, 2021
New Nanotechnology Delivers RNA Drugs Only to "Bad" Immune Cells
Inflammatory conditions are linked to an overactive immune system, and resolving them therapeutically often involves cal ...
JUL 20, 2021
Immunology
Coronavirus Variants No Match Against Newly-Discovered Antibody
JUL 20, 2021
Coronavirus Variants No Match Against Newly-Discovered Antibody
Over 940 million people around the world have been fully vaccinated. But, as the World Health Organization warns, t ...
JUL 18, 2021
Drug Discovery & Development
COVID-19 Antibiotic No More Effective than Placebo
JUL 18, 2021
COVID-19 Antibiotic No More Effective than Placebo
Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, do ...
AUG 07, 2021
Cancer
New Drug Combo Eliminates Pancreatic Cancer in Mice
AUG 07, 2021
New Drug Combo Eliminates Pancreatic Cancer in Mice
A combination of three immunotherapy drugs can eliminate pancreatic tumors in mice. The study was published in Canc ...
AUG 18, 2021
Cannabis Sciences
Cannabis Use Disorder Linked to COVID Hospitalization
AUG 18, 2021
Cannabis Use Disorder Linked to COVID Hospitalization
People with a genetic predisposition to cannabis use disorder (CUD) are more likely to require hospitalization after con ...
SEP 14, 2021
Drug Discovery & Development
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
SEP 14, 2021
A novel drug that targets the removal of pathogenic antibodies in myasthenia gravis
Myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness and fatigue. The disorder leads to a ...
Loading Comments...